Does Rallies show Form 4 insider transactions for BCAX?

Yes. Rallies tracks BCAX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BCAX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.

BCAX (Bicara Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAX trades at $20.43 with a market cap of $1.27B and a P/E ratio of -8.10. BCAX moved +2.05% today. Year to date, BCAX is +26.82%; over the trailing twelve months it is +35.84%. Its 52-week range spans $7.80 to $28.09. Analyst consensus is strong buy with an average price target of $30.99. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BCAX stock inside the company?

Recent BCAX insider activity includes Cohlhepp Ryan sold 8.00K, Cohlhepp Ryan sold 4.50K, Raben David sold 5.50K, Hyep Ivan sold 9.20K, and Mazumdar Claire sold 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BCAX Key Metrics

Key financial metrics for BCAX
Metric	Value
Price	$20.43
Market Cap	$1.27B
P/E Ratio	-8.10
EPS	$-2.52
Dividend Yield	0.00%
52-Week High	$28.09
52-Week Low	$7.80
Volume	4.42K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-137.95M
Gross Margin	0.00%

Recent BCAX Insider Trades

Cohlhepp Ryan sold 8.00K (~$162.34K) on May 15, 2026.
Cohlhepp Ryan sold 4.50K (~$91.31K) on May 15, 2026.
Raben David sold 5.50K (~$125.83K) on Apr 27, 2026.
Hyep Ivan sold 9.20K (~$211.61K) on Apr 21, 2026.
Mazumdar Claire sold 15.00K (~$354.15K) on Apr 20, 2026.

Latest BCAX News

Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND — May 12, 2026
Bicara Secures $161.8M, Holds $539.8M Cash, Q3 Ficerafusp Combo Trial — May 11, 2026
Bicara Therapeutics Launches Phase 3 FORTIFI-HN01 Trial and Raises $161.8M — Mar 30, 2026
Bicara’s Ficera Achieves 54% ORR, BofA Initiates Buy with $35 — Mar 25, 2026
Bicara Sets FORTIFY Trial at 1,500 mg Weekly Dose Versus Pembrolizumab, Mid-2027 Readout Target — Mar 6, 2026

BCAX Analyst Consensus

11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.99.

Common questions about BCAX

Who is trading BCAX stock inside the company?: Recent BCAX insider activity includes Cohlhepp Ryan sold 8.00K, Cohlhepp Ryan sold 4.50K, Raben David sold 5.50K, Hyep Ivan sold 9.20K, and Mazumdar Claire sold 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BCAX?: Yes. Rallies tracks BCAX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BCAX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.